A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19
Status:
Withdrawn
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo controlled study to evaluate the efficacy and
safety of MRx-4DP0004 in patients with COVID-19.
90 hospitalised patients will be enrolled and randomised (2:1) to receive MRx-4DP0004 or
placebo for up to 14 days.
MRx-4DP0004 is an immunomodulating Live Biotherapeutic Product (LBP) which is expected to
prevent or reduce the hyperinflammatory response to SARS-CoV-2 infection without impairing
viral clearance.